Long-Term Stock Portfolio: 10 Best Stocks for the Next Decade

6. AbbVie Inc. (NYSE:ABBV)

EPS Forward Long Term Growth (3-5 Year CAGR): 15.24%

Number of Hedge Fund Holders: 93

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares.

Earlier on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, which was up from $225. The firm highlighted AbbVie’s strong growth momentum and consistent operational execution. The firm downplayed concerns regarding competitive pressure from Tremfya, asserting that it is unlikely to pose a significant threat to Skyrizi’s market dominance.

In Q3 2025, AbbVie Inc. (NYSE:ABBV) reported total net revenues of ~$15.8 billion, representing a 9.10% year-over-year rise. This performance was driven by the explosive growth of newer immunology and neuroscience treatments. The company also earned $1.86 per share, beating estimates by $0.08. The immunology segment remained the company’s powerhouse, generating $7.9 billion in revenue, an 11.2% increase.

This growth was fueled by Skyrizi, which saw sales jump 46% to $4.7 billion, and Rinvoq, which rose 34.1% to ~$2.2 billion. These gains effectively cushioned the decline of Humira, which fell 55.7% to $993 million as biosimilar versions continued to erode its market share. Meanwhile, the oncology sector remained stable with $1.7 billion in revenue, as the growth of newer drugs like Venclexta balanced the impact of price negotiations on Imbruvica.

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.